Eluvia banner image

ELUVIA VS. BARE METAL STENTS

EMINENT 
Randomised Controlled Trial results

EMINENT Clinical Trial Results

EMINENT1 is the largest randomised Controlled Trial (2:1) comparing Eluvia™ Drug-Eluting Vascular Stent System to self-expanding bare metal stents (BMS) for SFA/PPA; EU multi-center; superiority trial; core lab adjudicated.

Filename
PI-1139102-ABEMINENTdatasheetEMEA-FINAL.pdf
Size
773 KB
Format
application/pdf
Download the EMINENT data sheet

EMINENT RCT 1-year primary patency results

Eluvia demonstrated superiority over BMS1 with a statistically significant primary patency of 85.4% versus 76.3% through 1-Year.

1-Year Primary Kaplen Meijer Patency estimate

EMINENT RCT 1-year primary sustained clinical improvement

Eluvia demonstrated a statistically significant greater rate of sustained clinical improvement without reintervention over BMS through 1-Year.5

EMINENT Trial Eluvia 1 Year Primary Sustained

EMINENT randomised controlled trial details

 Eluvia DES
(n=492)		BMS 
(n=273)		p-value
All Death, Major Amputation, TLR11.8% (56/474)11.8% (31/263)0.9912
All-Cause Death at 1-Year2.7% (13/474)1.1% (3/263)0.1528
Target Limb Major Amputation0.2% (1/474)0.0% (0/263)1.0000
Clinically-Driven Target Lesion Revascularization8.4% (40/474)10.6% (28/263)0.3212
icon-person-with-headset

Talk to a sales representative

Request a rep
icon-document-with-magnifying-glass

Discover more about Eluvia Drug-Eluting Stent

Explore further
icon-envelope-with-message

Stay updated on the latest DET news Register
 

Register

1. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication.  Primary Endpoint: 1-Year Binary Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077).

2. EMINENT Clinical Trial 12-Month results presented by Professor Yann Goueffic, MD. VIVA 2021

3. Kaplan-Meier Estimate: Primary patency defined as core-lab assessed duplex ultrasound peak systolic velocity ratio (PSVR) ≤ 2.4 at 1-year in the absence of clinically-driven TLR or bypass of the target lesion.

4. Log-rank p-value compares the entire K-M curves from time point zero to day 395 (full 1-year follow-up window)

5. In EMINENT, primary sustained clinical improvement was defined as an improvement (decrease) by at least 1 Rutherford category, without TLR.

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.